Keywords: Germany, AMNOG, IQWiG, Added therapeutic benefit, Reference pricing, VFA

German pharma criticizes new AMNOG vetting procedure

Article | 13 March 2012

Until recently, pharmaceutical companies could set prices for new drugs in Germany. But now their “monopoly is broken,” ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in